- Il presente studio ha valutato l’efficacia e la sicurezza di risankizumab nel trattamento di differenti tipi di psoriasi in pazienti con pregresso fallimento terapeutico, intolleranza o effetti collaterali verso uno o multipli farmaci biologici.
- Risankizumab si è dimostrato essere un agente biologico efficace, sicuro e ben tollerato per il trattamento di differenti tipi di psoriasi, tra cui forme severe (psoriasi pustolosa), aree difficili da trattare (unghie e cuoio capelluto) e artropatia psoriasica, determinando una risposta prolungata.
Psoriasis is a chronic relapsing immune-mediated inflammatory disease. Individuals show variable response to different biologics. Risankizumab is one of the most recently approved biologic agents for treating psoriasis which is a humanised immunoglobulin G1 monoclonal antibody that targets the p19 subunit of IL-23.1 Real-life reports regarding its effectiveness are still limited. This study was conducted at Al Hada Armed Forces Hospital, Saudi Arabia on nine adult psoriasis patients who showed failure, intolerance and/or side effects to one or more biologic agent and were shifted to risankizumab to document its effectiveness and safety in different clinical types of psoriasis. They were prescribed risankizumab 150 mg subcutaneous injection at baseline, four weeks then every 12 weeks for at least 28 weeks.
In conclusion, risankizumab proved to be effective, safe and tolerable biologic agent for treatment of different types of psoriasis including severe form (pustular psoriasis), difficult to treat areas (nail and scalp) and psoriatic arthritis with sustainable and durable response. It might be an excellent choice for psoriasis patients who failed other biologics. However, the limited number of patients and short duration of the study make it difficult to generalise its results to all settings.